MAIL

Chara		

PATENT AND TRADEMARE OFFICE							AMARIA OFFIC	E						
								- L	2026-4034 07/950,380					
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)									APPLICANT Wilson, et al.					
									FILING DATE September 22, 1992	GROUP 1205				
							PATEN	NT D	OCUMENTS	•				
, EXAMINER INITIAL		DOCUMENT NUMBER DATE							NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
INITIAL		1 1	MENT N	I I	T	Г	DATE		NAME	CLASS	SUBCLASS	II- AFFROPRIATE		
		$\vdash$	╁	╁	<u> </u>							-		
<b></b>			╂	├	ļ	<u> </u>				-	:			
										ļ	- 7:			
											<u> </u>			
											至			
											œ.			
			1	İ				_		1	- 5			
		ш	<u> </u>	I	<u> </u>	<u> </u>	FOREIGN PAT	TEN	IT DOCUMENTS			L		
									TRANSLATION					
	DOCUMENT NUMBER				DATE		COUNTRY		SUBCLASS	YES	NO			
					1									
		<del>                                     </del>	1			-				<b>!</b>		<b>-</b>		
										ļ				
,l.	L:_	LL_			L					L	l		L.,	
									nor, Title, Date, Pertinent Papers, Etc.)					
	1.		Holmes, F.A., et al., "Phase II Trail of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer", J. Natl. Cancer Inst., 83, No. 24, 1797-1805 (Dec. 18. 1991).											
421	2.	Extra, J.N	И., et a	al., "P	hase I	Trial o	of Taxotere", Proc	c. A	m. Assoc. Cancer Res. Annu. Meet., 32,	205, (Mar	ch 1991).			
	3.	Schmid, S.M., et al., "IFN 6 Augmentation of Taxol Anticellular Effect: Comparison with Taxol/Cisplatin or Taxol/Adriamycin in MCF-7 Breast Carcinoma Cells", J. Interferon Res. 11 (Suppl. 1) S237 (1991).												
0	4.	Fojo, A.7 269, (Jan			pressi	on of A	A Multidrug-Resis	stanc	ce Gene in Human Tumors and Tissues",	Proc. Natl.	Acad. Sci. U	SA 84, 20	55-	
EXAMINER	W	11/2	~	$\overline{\mathcal{F}}$	/				DATE CONSIDERED 5/2[	143				
								rman	ce with MPEP 609; Draw line through cit	ation if not	in conformar	nce and no	ot	
considered. In	clude copy	of this form	ı with ı	next co	mmun	iication	to applicant.							

FORM PTO-FB-AB20 (also form PTO-1449) Patent and Trademark Office - U.S. DEPARTMENT of COMMERCE